基质金属蛋白酶抑制剂类抗肿瘤药物临床研究进展

被引：20

作者：

韩艳珍

薛建鹏

胡加亮

徐寒梅

机构：

[1] 中国药科大学多肽药物创制工程研究中心

来源：

药学进展 | 2018年 / 42卷 / 02期

关键词：

基质金属蛋白酶; 基质金属蛋白酶抑制剂; 选择性; 抗肿瘤; 临床进展;

D O I：

暂无

中图分类号：

R979.1 [抗肿瘤、抗癌药物];

学科分类号：

100403 [营养与食品卫生学];

摘要：

基质金属蛋白酶是一类锌离子和钙离子依赖的蛋白水解酶,能够降解细胞外基质和基膜,在介导肿瘤血管新生、转移和侵袭等过程中发挥重要作用,基质金属蛋白酶抑制剂已成为当前抗肿瘤新药研发的热点之一。总结基质金属蛋白酶抑制剂用于抗肿瘤治疗的临床研究进展,为其进一步研究与应用提供参考。

引用

页码：129 / 137

页数：9

共 16 条

[1]

Peptidomimetic hydroxamate metalloproteinase inhibitors abrogate local and systemic toxicity induced by Echis ocellatus (saw-scaled) snake venom.[J].Ana Silvia Arias;Alexandra Rucavado;José María Gutiérrez.Toxicon.2017,

[2]

Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial [J].

Deplanque, Gael ;

Gervais, Radj ;

Vergnenegre, Alain ;

Falchero, Lionel ;

Souquet, Pierre-Jean ;

Chavaillon, Jean-Michel ;

Taviot, Bruno ;

Fraboulet, Ghislaine ;

Saal, Hakim ;

Robert, Caroline ;

Chosidow, Olivier .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (06) :1077-1085

[3]

Prevention of Abdominal Aortic Aneurysm Progression by Targeted Inhibition of Matrix Metalloproteinase Activity With Batimastat-Loaded Nanoparticles [J].

Nosoudi, Nasim ;

Nahar-Gohad, Pranjal ;

Sinha, Aditi ;

Chowdhury, Aniqa ;

Gerard, Patrick ;

Carsten, Christopher G. ;

Gray, Bruce H. ;

Vyavahare, Naren R. .

CIRCULATION RESEARCH, 2015, 117 (11) :E80-E89

[4]

Matrix metalloproteinases and their tissue inhibitors in gastric cancer as molecular markers [J].

Sampieri, Clara L. ;

Leon-Cordoba, Kenneth ;

Maria Remes-Troche, Jose .

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2013, 9 (03) :356-363

[5]

Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid [J].

Dedes, P. G. ;

Gialeli, Ch. ;

Tsonis, A. I. ;

Kanakis, I. ;

Theocharis, A. D. ;

Kletsas, D. ;

Tzanakakis, G. N. ;

Karamanos, N. K. .

BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2012, 1820 (12) :1926-1939

[6]

Third generation of matrix metalloprotease inhibitors: Gain in selectivity by targeting the depth of the S′1 cavity [J].

Devel, Laurent ;

Czarny, Bertrand ;

Beau, Fabrice ;

Georgiadis, Dimitris ;

Stura, Enrico ;

Dive, Vincent .

BIOCHIMIE, 2010, 92 (11) :1501-1508

[7]

Matrix metalloproteinase inhibitor, MMI270 (CGS27023A) inhibited hematogenic metastasis of B16 melanoma cells in both experimental and spontaneous metastasis models [J].

Kasaoka, Tatsuhiko ;

Nishiyama, Hiroko ;

Okada, Mikiko ;

Nakajima, Motowo .

CLINICAL & EXPERIMENTAL METASTASIS, 2008, 25 (07) :827-834

[8]

COL-3 benefits patients with AIDS-related Kaposi's sarcoma [J].

Furlow, B .

LANCET ONCOLOGY, 2006, 7 (05) :368-368

[9]

Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma [J].

Heath, EI ;

Burtness, BA ;

Kleinberg, L ;

Salem, RR ;

Yang, SC ;

Heitmiller, RF ;

Canto, MI ;

Knisely, JPS ;

Topazian, M ;

Montgomery, E ;

Tsottles, N ;

Pithavala, Y ;

Rohmiller, B ;

Collier, M ;

Forastiere, AA .

INVESTIGATIONAL NEW DRUGS, 2006, 24 (02) :135-140

[10]

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study.[J].H. Hirte;I.B. Vergote;J.R. Jeffrey;R.N. Grimshaw;S. Coppieters;B. Schwartz;D. Tu;A. Sadura;M. Brundage;L. Seymour.Gynecologic Oncology.2005, 2

← 1 2 →